

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited (ASX:PBT)
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Mr. Lawrence Gozlan
Date of Last Notice:	12 th December 2012

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct														
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	-														
Date of change	19 th December 2017														
No. of securities held prior to change	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: center;">1,000,000*</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">-</td> <td style="text-align: center;">1,000,000</td> </tr> </tbody> </table>				Shares	Options	Direct	-	1,000,000*	Indirect	-	-	Total	-	1,000,000
	Shares	Options													
Direct	-	1,000,000*													
Indirect	-	-													
Total	-	1,000,000													
	*options lapsed														
Class	Unlisted Options														
Number acquired	<table border="1" style="width: 100%;"> <thead> <tr> <th></th> <th>Shares</th> <th>Options</th> </tr> </thead> <tbody> <tr> <td>Direct</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Indirect</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> </tr> <tr> <td>Total</td> <td style="text-align: center;">-</td> <td style="text-align: center;">1,250,000</td> </tr> </tbody> </table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	1,250,000
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	1,250,000													

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Shares	Options	
	Direct	-	-
	Indirect	-	-
	Total	-	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	As detailed in the Explanatory Memorandum which accompanied and formed part of the 2017 Notice of Annual General Meeting of the Company.		
No. of securities held after change	Shares	Options	
	Direct	-	-
	Indirect	-	-
	Total	-	1,250,000
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Exercise of options by employer share option plan.		

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 - +Closed Period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided on what date was this provided?	N/A



22 Dec 2012

+ See chapter 19 for defined terms.